AustraliaHealth

Fisher & Paykel Healthcare (ASX:FPH) increased its 2027 profit guidance to $525–565 million, citing strong hardware demand.

Telix Pharmaceuticals (ASX:TLX) reported group revenue of US$477 million for the first half of 2026.

Sonic Healthcare (ASX:SHL) reported $10.87 billion in annual revenue for FY26, marking a 13% increase.

Alcidion Group (ASX:ALC) reported a 27% increase in FY26 revenue to $51.6 million alongside record profitability metrics.

Healius (ASX:HLS) reported a group underlying revenue of $1.37 billion and an underlying EBIT of $30.2 for the financial year ended June 30.

Biotech firm Nyrada (ASX:NYR) released its 2026 financial year audited accounts, showing $8.4 million in cash reserves as of June 30.

HealthCo Healthcare and Wellness REIT (ASX:HCW) narrowed its net loss to $49.7 million in fiscal 2026, down from $89.3 million a year prior.

Pro Medicus (ASX:PME) reported a full-year revenue of $261.7 million for the period ended June 30.

CSL (ASX:CSL) reported a US$2.6 billion net loss after tax for FY26 as one-off restructuring costs and impairments offset underlying earnings.

Doctor Care Anywhere (ASX:DOC) reported total revenue of £20.4 million for the six months ended June 30.

OncoSil Medical (ASX:OSL) secured U.S. FDA approval for its OncoSil device to treat distal cholangiocarcinoma, targeting an $80 million market.

Australian Clinical Labs (ASX:ACL) reported an underlying net profit of $35.5 million for the 2026 financial year.